PDGFRB and plasma cell myeloma: In a preclinical study it was shown that PDGF-B/PDGFRβ pathway promoted tumor growth and vessel sprouting in multiple myeloma, and dasatinib, a PDGFRβ/Src inhibitor delayed tumor growth and angiogenesis [113].